The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma

International Immunopharmacology

Volumn 38, Issue , 2016, Pages 81-89

  Wang, Sheng Dong ^a   Li, Heng Yuan ^a   Li, Bing Hao ^a   Xie, Tao ^a   Zhu, Ting ^a   Sun, Ling Ling ^a   Ren, Hai Yong ^a   Ye, Zhao Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Checkpoint inhibitor; CTLA 4; Immunotherapy; Osteosarcoma; PD 1

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TICILIMUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; MALIGNANT MESOTHELIOMA; MELANOMA; METASTASIS; METASTATIC MELANOMA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR IMMUNOLOGY; UNSPECIFIED SIDE EFFECT; ANIMAL; BONE TUMOR; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNITY; IMMUNOTHERAPY; OSTEOSARCOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84974593746     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.05.016     Document Type: Review

References (139)

1. J. Ritter, and S.S. Bielack Osteosarcoma Ann. Oncol. 21 Suppl. 7 2010 (p. vii320-5)
2. J.S. Biermann, and et al. Bone cancer J. Natl. Compr. Cancer Netw. 8 6 2010 688 712
3. S.S. Bielack, and et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J. Clin. Oncol. 20 3 2002 776 790
4. S. Ferrari, and et al. The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future Cancer Treat. Res. 152 2009 275 287
5. S.M. Botter, D. Neri, and B. Fuchs Recent advances in osteosarcoma Curr. Opin. Pharmacol. 16 2014 15 23
6. N.P. Restifo, M.E. Dudley, and S.A. Rosenberg Adoptive immunotherapy for cancer: harnessing the T cell response Nat. Rev. Immunol. 12 4 2012 269 281
7. S.L. Topalian, G.J. Weiner, and D.M. Pardoll Cancer immunotherapy comes of age J. Clin. Oncol. 29 4836 2011 4828 4836
8. S.A. Rosenberg, P. Spiess, and R. Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 4770 1986 1318 1321
9. A.I. Sperling, and J.A. Bluestone The complexities of T-cell co-stimulation: CD28 and beyond Immunol. Rev. 153 1996 155 182
10. A. Tafuri, and et al. ICOS is essential for effective T-helper-cell responses Nature 409 6816 2001 105 109
11. L. Chen, and D.B. Flies Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 13 4 2013 227 242
12. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 4 2012 252 264
13. S.L. Topalian, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 26 2012 2443 2454
14. J.R. Brahmer, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 26 2012 2455 2465
15. R.E. Royal, and et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J. Immunother. 33 8 2010 828 833
16. M.A. Curran, and et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U. S. A. 107 9 2010 4275 4280
17. R.B. Holmgaard, and et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 J. Exp. Med. 210 7 2013 1389 1402
18. F.S. Hodi, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 8 2010 711 723
19. J.K. Shen, and et al. Programmed cell death ligand 1 expression in osteosarcoma Cancer Immunol. Res. 2 7 2014 690 698
20. W. Wang, and et al. Cytotoxic T-lymphocyte antigen-4 + 49G/A polymorphism is associated with increased risk of osteosarcoma Genet. Test. Mol. Biomarkers 15 7-8 2011 503 506
21. Y. Liu, and et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma DNA Cell Biol. 30 12 2011 1051 1055
22. R. Ferris PD-1 targeting in cancer immunotherapy Cancer 119 23 2013 E1 E3
23. T.L. Walunas, and et al. CTLA-4 can function as a negative regulator of T cell activation Immunity 1 5 1994 405 413
24. Y. IIshida, and et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 11 11 1992 3887 3895
25. J.F. Brunet, and et al. A new member of the immunoglobulin superfamily-CTLA-4 Nature 328 6127 1987 267 270
26. H. Nishimura, and et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes Int. Immunol. 8 5 1996 773 780
27. T. Lindsten, and et al. Characterization of CTLA-4 structure and expression on human T cells J. Immunol. 151 7 1993 3489 3499
28. K.A. Sheppard, and et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta FEBS Lett. 574 1-3 2004 37 41
29. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J. Exp. Med. 182 2 1995 459 465
30. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response Clin. Cancer Res. 19 19 2013 5542
31. D.B. Page, and et al. Immune modulation in cancer with antibodies Annu. Rev. Med. 65 2014 185 202
32. R.V. Parry, and et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol. Cell. Biol. 25 21 2005 9543 9553
33. P.S. Linsley, and J.A. Ledbetter The role of the CD28 receptor during T cell responses to antigen Annu. Rev. Immunol. 11 1993 191 212
34. C.H. June, and et al. The B7 and CD28 receptor families Immunol. Today 15 7 1994 321 331
35. C.B. Thompson, and et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines Proc. Natl. Acad. Sci. U. S. A. 86 4 1989 1333 1337
36. J.M. Green, and et al. Absence of B7-dependent responses in CD28-deficient mice Immunity 1 6 1994 501 508
37. K. Harper, and et al. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location J. Immunol. 147 3 1991 1037 1044
38. A.V. Collins, and et al. The interaction properties of costimulatory molecules revisited Immunity 17 2 2002 201 210
39. P.J. Darlington, and et al. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation J. Immunol. 175 2 2005 996 1004
40. P.S. Linsley, and et al. CTLA-4 is a second receptor for the B cell activation antigen B7 J. Exp. Med. 174 3 1991 561 569
41. R.H. Schwartz Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy Cell 71 7 1992 1065 1068
42. M.L. Alegre, and et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells J. Immunol. 157 11 1996 4762 4770
43. C.A. Chambers, M.S. Kuhns, and J.P. Allison Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses Proc. Natl. Acad. Sci. U. S. A. 96 15 1999 8603 8608
44. S. Read, V. Malmstrom, and F. Powrie Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation J. Exp. Med. 192 2 2000 295 302
45. V.A. Pedicord, and et al. Single dose of anti-CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance Proc. Natl. Acad. Sci. U. S. A. 108 1 2011 266 271
46. N. Jain, and et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity Proc. Natl. Acad. Sci. U. S. A. 107 4 2010 1524 1528
47. J.G. Egen, M.S. Kuhns, and J.P. Allison CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat. Immunol. 3 7 2002 611 618
48. L. Vijayakrishnan, and et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells Immunity 20 5 2004 563 575
49. A. Boasso, and et al. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4 + T cells Blood 105 4 2005 1574 1581
50. U. Grohmann, and et al. CTLA-4-Ig regulates tryptophan catabolism in vivo Nat. Immunol. 3 11 2002 1097 1101
51. R. Menta, and et al. Tryptophan concentration is the main mediator of the capacity of adipose mesenchymal stromal cells to inhibit T-lymphocyte proliferation in vitro Cytotherapy 16 12 2014 1679 1691
52. D.H. Munn, and et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism J. Exp. Med. 189 9 1999 1363 1372
53. O.S. Qureshi, and et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 Science 332 6029 2011 600 603
54. B.M. Carreno, and et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression J. Immunol. 165 3 2000 1352 1356
55. D. Li, and et al. Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation J. Immunol. 173 12 2004 7135 7139
56. H. Schneider, and et al. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization Eur. J. Immunol. 38 1 2008 40 47
57. C. Guntermann, and D.R. Alexander CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases J. Immunol. 168 4429 2002 4420 4429
58. K.A. Frauwirth, and et al. The CD28 signaling pathway regulates glucose metabolism Immunity 16 6 2002 769 777
59. K.F. Kong, and et al. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function Nat. Immunol. 15 5 2014 465 472
60. X. Zhang, and et al. Structural and functional analysis of the costimulatory receptor programmed death-1 Immunity 20 3 2004 337 347
61. S.P. Sidorenko, and E.A. Clark The dual-function CD150 receptor subfamily: the viral attraction Nat. Immunol. 4 1 2003 19 24
62. E.O. Long Regulation of immune responses through inhibitory receptors Annu. Rev. Immunol. 17 1999 875 904
63. J.M. Chemnitz, and et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J. Immunol. 173 2 2004 945 954
64. J.L. Riley PD-1 signaling in primary T cells Immunol. Rev. 229 1 2009 114 125
65. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int. Immunol. 19 7 2007 813 824
66. M.E. Keir, and et al. PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 2008 677 704
67. G.J. Freeman, and et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J. Exp. Med. 192 7 2000 1027 1034
68. Y. Latchman, and et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat. Immunol. 2 3 2001 261 268
69. T. Yamazaki, and et al. Expression of programmed death 1 ligands by murine T cells and APC J. Immunol. 169 10 2002 5538 5545
70. M.J. Eppihimer, and et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells Microcirculation 9 2 2002 133 145
71. K. English, and et al. IFN- and TNF-differentially regulate immunomodulation by murine mesenchymal stem cells Immunol. Lett. 110 2 2007 91 100
72. Y. Rui, T. Honjo, and S. Chikuma Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response Proc. Natl. Acad. Sci. 110 40 2013 16073 16078
73. L.M. Francisco, P.T. Sage, and A.H. Sharpe The PD 1 pathway in tolerance and autoimmunity Immunol. Rev. 236 1 2010 219 242
74. L.M. Francisco, and et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J. Exp. Med. 206 13 2009 3015 3029
75. H.J. Park, and et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8 + T cell immune response via the interaction with PD-L1 expressed on CD8 + T cells J. Immunol. 194 12 2015 5801 5811
76. P. Penaloza-MacMaster, and et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection J. Exp. Med. 211 9 2014 1905 1918
77. L. Wang, and et al. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 + CD4 + regulatory T cells Proc. Natl. Acad. Sci. U. S. A. 105 27 2008 9331 9336
78. J. Liu, and et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 110 1 2007 296 304
79. A.T. Parsa, and et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat. Med. 13 1 2007 84 88
80. S.C. Liang, and et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses Eur. J. Immunol. 33 10 2003 2706 2716
81. X. Zhong, and et al. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding Eur. J. Immunol. 37 9 2007 2405 2410
82. H. Kaku, and T.L. Rothstein Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter Genes Immun. 11 1 2010 55 66
83. D.L. Barber, and et al. Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 7077 2006 682 687
84. E.J. Wherry T cell exhaustion Nat. Immunol. 12 6 2011 492 499
85. K.A. Hofmeyer, H. Jeon, and X. Zang The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion J. Biomed. Biotechnol. 2011 2011 451694
86. M. Quigley, and et al. Transcriptional analysis of HIV-specific CD8 + T cells shows that PD-1 inhibits T cell function by upregulating BATF Nat. Med. 16 10 2010 1147 1151
87. E.A. Said, and et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4 + T cell activation during HIV infection Nat. Med. 16 4 2010 452 459
88. M.M. Staron, and et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection Immunity 41 5 2014 802 814
89. R.M. Wong, and et al. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression Immunol. Lett. 127 1 2009 60 67
90. M.E. Keir, and et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance J. Exp. Med. 203 4 2006 883 895
91. M.J. Butte, and et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 1 2007 111 122
92. Y. Han, and et al. Human CD14 + CTLA-4 + regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma Hepatology 59 2 2014 567 579
93. N. Erfani, and et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) Lung Cancer 77 2 2012 306 311
94. H. Mao, and et al. New insights of CTLA-4 into its biological function in breast cancer Curr. Cancer Drug Targets 10 7 2010 728 736
95. H. Yu, and et al. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis Cancer Immunol. Immunother. 64 7 2015 853 860
96. H. Kakavand, and et al. Tumor PD-L1 expression, immune cell correlates and PD-1 + lymphocytes in sentinel lymph node melanoma metastases Mod. Pathol. 2015
97. K. Waki, and et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer Cancer Sci. 105 10 2014 1229 1235
98. R.H. Thompson, and et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin. Cancer Res. 13 6 2007 1757 1761
99. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol. 8 6 2008 467 477
100. K. Azuma, and et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer Ann. Oncol. 25 10 2014 1935 1940
101. D. Massi, and et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics Ann. Oncol. 25 12 2014 2433 2442
102. S. Kim, and et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas Eur. J. Cancer 2015
103. Y. Ohigashi, and et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin. Cancer Res. 11 8 2005 2947 2953
104. P. Hingorani, and et al. Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients J. Immunother. Cancer 3 2015 35
105. F. Yu, and J. Miao Significant association between cytotoxic T lymphocyte antigen 4 + 49G > A polymorphism and risk of malignant bone tumors Tumour Biol. 34 6 2013 3371 3375
106. W. Zheng, and et al. Expression of programmed death 1 is correlated with progression of osteosarcoma APMIS 123 2 2015 102 107
107. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736
108. K.S. Peggs, S.A. Quezada, and J.P. Allison Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy Immunol. Rev. 224 2008 141 165
109. F. Hirano, and et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res. 65 3 2005 1089 1096
110. C. Blank, and et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells Cancer Res. 64 3 2004 1140 1145
111. C. Robert, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 2526 2011 2517 2526
112. J.D. Wolchok, and et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol. 11 2 2010 155 164
113. A.M. Eggermont, and et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Lancet Oncol. 16 5 2015 522 530
114. Calabro, L., et al., Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol., 2013. 14(11): p. 1104-1111.
115. J.S. Weber, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol. 16 4 2015 375 384
116. C. Robert, and et al. Pembrolizumab versus Ipilimumab in advanced melanoma N. Engl. J. Med. 372 26 2015 2521 2532
117. T. Powles, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 7528 2014 558 562
118. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr. Opin. Immunol. 24 2 2012 207 212
119. A. Sivan, and et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 2015
120. M. Vetizou, and et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Science 350 6264 2015 1079 1084
121. R. Das, and et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo J. Immunol. 194 3 2015 950 959
122. A.S. Sheik, and et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade JAMA Dermatol. 151 2 2015 195 199
123. B. Kavanagh, and et al. CTLA4 blockade expands FoxP3 + regulatory and activated effector CD4 + T cells in a dose-dependent fashion Blood 112 4 2008 1175 1183
124. M. Ahmadzadeh, and et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 8 2009 1537 1544
125. J. Larkin, and et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 373 1 2015 23 34
126. A.B. Sharabi, and et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen Cancer Immunol. Res. 3 4 2015 345 355
127. J. Duraiswamy, and et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res. 73 12 2013 3591 35603
128. S.M. Mangsbo, and et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy J. Immunother. 33 3 2010 225 235
129. Z. Li, and et al. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate J. Orthop. Res. 30 5 2012 824 830
130. B. Li, and et al. Induction of a specific CD8 + T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma Oncotarget 5 21 2014 10791 10802
131. D.M. Lussier, and et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions J. Immunother. 38 3 2015 96 106
132. D.M. Lussier, and et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma J. Immunother. Cancer 3 2015 21
133. M. Kawano, and et al. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma Oncol. Rep. 29 3 2013 1001 1006
134. M.A. Curran, and et al. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production PLoS One 6 4 2011 e19499
135. W.L. Redmond, S.N. Linch, and M.J. Kasiewicz Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity Cancer Immunol. Res. 2 2 2014 142 153
136. C.J. Voskens, and et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PLoS One 8 1 2013 e53745
137. J.S. Weber, and et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 9 2013 1675 1682
138. J.R. Brahmer, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol. 28 19 2010 3167 3175
139. M.A. Postow, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N. Engl. J. Med. 372 21 2015 2006 2017